(Q38148782)

29 August 2017

title

Vaccines based on structure-based design provide protection against infectious diseases (English)

1 reference

29 August 2017

1 reference

Sunil Thomas

1

1 reference

29 August 2017

Bruce A Luxon

series ordinal

2

1 reference

29 August 2017

publication date

4 October 2013

1 reference

Expert Review of Vaccines

29 August 2017

published in

1 reference

29 August 2017

volume

12

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1301-1311

1 reference

Infection with chikungunya virus in Italy: an outbreak in a temperate region

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Modeling the epidemic waves of AH1N1/09 influenza around the world.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Norovirus outbreak in a cruise ship sailing around the British Isles: investigation and multi-agency management of an international outbreak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Unmanageable norovirus outbreak in a single resort located in the Dominican Republic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Development of stable influenza vaccine powder formulations: challenges and possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Specific immunization issues in the occupational health setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Host-Salmonella interaction: human trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Attenuated vaccines can recombine to form virulent field viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris: high-level production and immunological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Production and purification of a recombinant Staphylococcal enterotoxin B vaccine candidate expressed in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Recombinant protein vaccines produced in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Large-scale extraction of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Genetically engineered vaccines: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Antigen identification starting from the genome: a "Reverse Vaccinology" approach applied to MenB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Identification of Ehrlichia ruminantium proteins that activate cellular immune responses using a reverse vaccinology strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Genome-wide screening and identification of antigens for rickettsial vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Genomic approach for analysis of surface proteins in Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Reverse vaccinology, a genome-based approach to vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Rational design of a meningococcal antigen inducing broad protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based antigen design: a strategy for next generation vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

A novel strategy of epitope design in Neisseria gonorrhoeae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Peptidomimetics: modifying peptides in the pursuit of better vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based vaccines provide protection in a mouse model of ehrlichiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Progress and obstacles in vaccine development for the ehrlichioses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Antigenic protein modifications in Ehrlichia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Exit mechanisms of the intracellular bacterium Ehrlichia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

The Lyme disease vaccine--a public health perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Exploiting Antigenic Diversity for Vaccine Design: THE CHLAMYDIA ArtJ PARADIGM

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Antibody vs. HIV in a clash of evolutionary titans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

The rational design of an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based vaccine design in HIV: blind men and the elephant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Identifying epitopes of HIV-1 that induce protective antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structural definition of a conserved neutralization epitope on HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Progress in the rational design of an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Limitations to the structure-based design of HIV-1 vaccine immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based design of NS2 mutants for attenuated influenza A virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

A highly conserved neutralizing epitope on group 2 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Broadly neutralizing antibodies against influenza virus and prospects for universal therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based design for high-hanging vaccine fruits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structure-based Design of a Second-generation Lyme Disease Vaccine Based on a C-terminal Fragment of Borrelia burgdorferi OspA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Structural vaccinology starts to deliver

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

Genome Analysis Reveals Pili in Group B Streptococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.840092

10.1586/14760584.2013.840092

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference